Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V181 vs Butantan-DV in Healthy Adults in Brazil
NCT05710224Phase 2Completed
- Sponsor
- Instituto Butantan
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TetraVax-DV in dengue fever (2 arms), sponsored by Instituto Butantan. Primary endpoints: Dengue Virus Neutralizing Antibody Titers at 28 days, Seroconversion Rate at 28 days and 1 more. Started Feb 2023; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05710224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710224.